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To examine the risk of hypospadias after exposure to loratadine and other antihistamines during pregnancy, we 
conducted a population-based case-control study in four Danish counties, which account for 30% of the Danish 
population (~1.6 M). We obtained data on maternal use of antihistamines from prescription databases, and data on birth 
outcomes from the Danish Medical Birth Registry (MBR) and the Hospital Discharge Registry (HDR). A total of 65,383 
male births with a full prescription history of the mother in the study period from 1989-2002 were available for analysis. 
Within this cohort, we identified cases with a diagnosis of hypospadias, and 10 selected controls per case without such a 
diagnosis (matched on birth month, gender and year of birth). We identified 227 cases of hypospadias recorded in the 
HDR within six months postpartum and 2270 controls. One c a s e  ( 0 . 4 % )  a n d  e i g h t  ( 0 . 4 % )  c o n t r o l s  w e r e  e x p o s e d  t o  
loratadine in the first trimester and up to 30 days before the time of conception. The adjusted odds ratio (OR) for 
hypospadias among users of loratadine relative to non-users was 1.4 (95% CI: 0.2-11.2) and the corresponding OR for 
other antihistamines was 1.9 (95% CI: 0.7-5.7).  In this study, maternal exposure to loratadine did not appear to be 
associated with an increased risk of hypospadias when compared with other antihistamines, although it should be noted 
that the statistical precision of the risk estimates might be limited. 
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1.  Introduction 
Hypospadias occurs with a reported prevalence 
of 0.3% to 0.8% and since the 1970s, multiple reports 
from the United States, England, Scandinavia, and 
Hungary have shown an increase in the occurrence of 
hypospadias [1-7]. Although very few risk factors for 
hypospadias are established, gestational and pre-
existing diabetes, intrauterine growth retardation, 
paternal subfertility, in vitro fertilization (IVF), 
maternal age, and genetic factors have all been 
suggested to be associated with an increased risk of 
hypospadias [8-17].   
Loratadine is a non-sedating antihistamine 
commonly used for seasonal allergies [18]. In 2001, a 
report from Sweden suggested an association 
between maternal use of loratadine and infant 
hypospadias [19]. Having considered year of birth, 
maternal age, and parity, the odds ratio (OR) for 
hypospadias in relation to loratadine exposure was 
2.39 (95% confidence interval [CI]: 1.43-3.38). The 
study also compared the occurrence of hypospadias 
after the use of other antihistamines. The OR for 
having a diagnosis of hypospadias in the Swedish 
Medical Birth Registry (MBR) after maternal use of 
loratadine compared with maternal use of other anti-
allergic anti-histamines was 4.0 (95% CI:1.42-12.9) 
[19].  
Neither a recent study from Israel including 210 
pregnant women exposed to loratadine [20] nor a 
study that used data from four countries and 
included 161 pregnant women exposed to loratadine 
[21] found an increased risk of hypospadias. 
However, these studies had limited power and due to 
the low prevalence of hypospadias not one case could 
be expected. Recently, the American Centers of 
Disease Control and Prevention (CDC) reported a 
case-control study including 563 infants with second- 
or third-degree hypospadias [22]. This study did not 
find any association between loratadine use and 
hypospadias. But since first-degrees hypospadias was 
excluded CDC could not assess the potential 
association between the mildest form of hypospadias 
and loratadine.  Since use of anti-allergic drugs is 
common, any causal association may have major 
public health implications. We, therefore, conducted a 
case-control study in Denmark based on hospital 
discharge data of cases with hypospadias and 
population controls linked to Danish prescription 
registries.  
2.  Materials and methods 
Study population 
The study was conducted in the four Danish 
counties of North Jutland, Aarhus, Viborg and 
Ringkoebing which account for 30% of the Danish 
population (~1.6 M). A total of 65,383 male births 
with a full prescription history of the mother were 
available for analyses in the study period from 1989-
2002 (North Jutland n=34,859), 1996-2002 (Aarhus 
n=20,382) and 1998-2002 (Viborg n=4,148) and 
(Ringkoebing n=5,994).   
Cases of hypospadias 
We identified all cases of hypospadias in the 
period 1989-2003 from the nationwide Hospital 
Discharge Registry (HDR). This Registry comprises of 
data on all discharges from hospitals in Denmark and 
includes  10-digit personal identifiers, dates of 
admission and discharge, surgical procedures, and up 
to 20 diagnoses [23] classified according to the Danish 
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Diseases, 8th Revision (ICD-8) until the end of 
1993 and ICD-10 thereafter (ICD-9 was never used in 
Denmark). The codes for hypospadias in ICD-8 are 
752.20 (hypospadia glandis, n=3), 752.21 (hypospadia 
corporis penis, n=1), 752.22 (hypospadia scrotalis, 
n=0), 752.28 (hypospadia alia definite, n=0), 752.29 
(hypospadia, n=5); in ICD-10, the codes are Q54.0 
(hypospadia glandis, n=101), Q54.1 (hypospadia 
corporis penis, n=11), Q54.2 (hypospadia 
penoscrotalis, n=0), Q54.3 (hypospadia perinealis, 
n=2), Q54.4 (hypospadia penis arcuatos, n=3), Q54.8 
(other specified hypospadias, n=0), Q54.9 
(hypospadias without any specifications, n=135); 
There were 159 children with multiple hypospadias 
codes, and 25 children with both ICD-8 and ICD-10 
codes. Using these codes, a total of 319 cases of 
hypospadias were identified (anytime postpartum) in 
the cohort of 65,383 male births in the four counties.  
The Danish Medical Birth Registry 
The MBR, which comprises of data collected by 
midwives and doctors attending deliveries, contains 
information on all births in Denmark since 1 January 
1973 [24,25]. The main data constitute maternal age, 
self-reported smoking status at first antenatal visit, 
birth order, stillbirth, Apgar score, gestational age, 
height and weight of the neonate, and personal 
identifiers for both mother and child [24].  
Use of loratadine, other antihistamines, IVF drugs, 
antidiabetics and epileptics 
As a part of the tax-funded healthcare for all 
inhabitants, the Danish National Health Service 
reimburses part of the patient expenditure on a wide 
range of prescribed drugs [21,26]. Danish patients are 
served by pharmacies equipped with electronic 
accounting systems that are used primarily to secure 
reimbursement for the National Health Service in 
each county. These systems include information on 
WHO’s Anatomical Therapeutic Chemical (ATC) 
classification code, the amount of the drug prescribed, 
the personal identification number, and the date of 
drug dispension. Since January 1 1989 all data from 
North Jutland County have been stored in a 
prescription database maintained by the Department 
of Clinical Epidemiology, Aarhus University Hospital 
and since 2000 the Department of Clinical 
Epidemiology has also maintained similar research 
prescription databases from the three other counties. 
The data from these three counties are available from 
January 1, 1996 (Aarhus County) and January 1, 1998 
(Ringkoebing and Viborg counties). Drugs sold over 
the counter are not available in these Prescriptions 
databases 
Among cases and controls, prescriptions on 
loratadine (ATC codes: R06AX13), other 
antihistamines (ATC code: R06, except R06AX13), 
clomifene (ATC code: G03GB02), antidiabetics (ATC 
code: A10) and epileptics (ATC code: N03) was 
obtained from the prescription databases.  
Data on preeclampsia 
From the HDR we also obtained information on 
preeclampsia (ICD-8 codes: 637.03, 637.04, 637.09, 
637.19; ICD-10 codes: 014, 015), since this has been 
found to be associated with hypospadias. The unique 
personal identifiers (CPR-numbers) were used to link 
records from all registries. 
Statistical analysis 
The association between use of loratadine and 
hypospadias was studied in a nested case-control 
design within the cohort of women who had a 
livebirth or a stillbirth after  the 28th week of 
gestation. Use of loratadine was classified into three 
groups  according to the time of exposure. The first 
trimester is considered the critical period for organ 
formation. Thus, the primary focus was the "early 
pregnancy" group, comprising of women who filled a 
p r e s c r i p t i o n  w i t h i n  3 0  d a y s  b e f o r e  c o n c e p t i o n  
("conception" was defined as the first day of last 
menstrual period [LMP]) up to the end of the first 
trimester (week 14 after the LMP). A second group 
comprised of women who filled a prescription within 
the first six months of pregnancy. A third group, the 
"entire pregnancy" group, comprised of women who 
filled prescriptions for loratadine at any time during 
pregnancy. Users of other antihistamines were 
classified similarly.  
We restricted the first analysis to the pregnancies 
where the women lived in the four counties during 
the complete study period, which was the period 
between 30 days before conception and six months 
post-delivery. In the first analysis, cases were defined 
as boys with hypospadias recorded in the HDR 
during the first six months post-delivery. 
The controls were selected from the study 
population of 65,383 male births. The control group 
comprised of 10 controls per case, and these controls 
had no recorded diagnosis of hypospadias during the 
first six months post delivery. We matched on birth, 
month, and year of the child. To examine whether the 
restriction of the hypospadias diagnosis to six months 
post-delivery had any impact on the results, we 
conducted a second analysis in which we defined 
cases as boys with hypospadias recorded in the HDR 
any time post-delivery (some children might have 
been coded later e.g. at the time of surgery) and 
controls as boys with no recorded diagnosis of 
hypospadias during the study period. In this analysis, 
cases and controls had to have lived in the four 
counties until the cases were diagnosed.  
For the main study variables, we constructed 
contingency tables between exposure to loratadine, 
other antihistamines, case/control status and possible 
confounders. We used exact conditional logistic 
regression to estimate the relative risk by virtue of the 
OR of hypospadias associated with exposure to 
loratadine adjusted for maternal age, birth order, 
smoking status, preeclampsia, use of clomifene (a 
proxy for IVF), diabetes, and epilepsy. The analyses 
were done using SAS version 9.1 (SAS Inc., Cary, NC, 
USA). 
3.  Results 
We identified 227 cases of hypospadias and 2270 
matched controls when considering diagnosis within 
six months postpartum. Descriptive data for cases 
and controls are shown in Table 1. A total of one case 
and eight controls were exposed to loratadine in the 
first trimester or up to 30 days before the time of 
conception compared with four cases and 23 controls Int. J. Med. Sci. 2006, 3 
 
23
exposed to other antihistamines in the first trimester 
or up to 30 days before the time of conception. 
Table 2 shows the ORs for hypospadias 
associated with exposure to loratadine and other 
antihistamines according to the time of exposure. The 
adjusted OR for loratadine exposure within 30 days 
before conception and during the first trimester was 
1.4 (95% CI: 0.0-10.5). The adjusted OR for other 
antihistamines was 1.9 (95% CI: 0.5-5.8). The crude 
and adjusted odds ratios were similar, suggesting that 
the variables we controlled for were no major 
confounders.  
For the second group, who filled the prescription 
within the first six month of pregnancy, and the third, 
"entire pregnancy" group, the adjusted ORs for 
loratadine exposure were 0.8 (95% CI: 0.0-4.9) and 0.5 
(95% CI: 0.0-3.3), respectively. The adjusted ORs for 
other antihistamines were 1.6 (95% CI: 0.3-5.5) and 1.0 
(95% CI: 0.2-3.4), respectively. 
Table 1.  Characteristics of 227 cases of hypospadias recorded 
within six months postpartum and 2270 control subjects. 
Variable Cases   
N (%) 
Controls  
N (%) 
Exposure to Loratadine*
  1 (0.4)  22 (1.0) 
   30 days before conception and first trimester  1 (0.4)  8 (0.4) 
   First trimester and second trimester  1 (0.4)  15 (0.7) 
   During pregnancy  1 (0.4)  21 (0.9) 
Exposure to other antihistamines*
  4 (1.8)  40 (1.8) 
   30 days before conception and first trimester  4 (1.8)  23 (1.0) 
   First trimester and second trimester  3 (1.3)  21 (0.9) 
   During pregnancy  3 (1.3)  30 (1.3) 
Maternal age      
     <25  41 (18.1)  319 (14.1) 
     25-30  99 (43.6)  1,036 (45.6) 
     >30  87 (38.3)  915 (40.3) 
Birth order    
     1  108 (47.6)  942 (41.5) 
     1+  119 (52.4) 1,328 (58.5) 
Smoking 1991-2002     
     Yes  51 (22.5)  524 (23.1) 
     No  156 (68.7) 1,571 (69.2) 
     Missing  20 (8.8)  175 (7.7) 
Gestational age    
     ≥37 weeks  198 (87.2) 2,160 (95.2) 
     34-36 weeks  20 (8.8)  81 (3.6) 
     <34 weeks  9 (4.0)  29 (1.3) 
Prescription for ovulation-inducing drugs  1 (0.4)  44 (1.9) 
Maternal epilepsy  2 (0.9)  13 (0.6) 
Maternal diabetes  1 (0.4)  8 (0.4) 
Preeclampsia  13 (5.7)  48 (2.1) 
*Exposure during pregnancy and 30 days before conception 
 
Considering all cases of hypospadias recorded 
anytime post-delivery (N=319), the risk estimates did 
not change markedly. The adjusted OR for exposure 
to loratadine in the first trimester and 30 days before 
conception was 1.1 (95% CI: 0.0-7.7), and the OR for 
exposure to other antihistamines in the same period 
was 1.7 (95% CI: 0.5-4.7). The adjusted OR for 
exposure to loratadine within the first six months of 
pregnancy was 0.6 (95% CI 0.0-3.8) and for the entire 
pregnancy 0.5 (95% CI 0.0-2.7). The adjusted ORs for 
other antihistamines were 1.1 (95% CI: 0.2-3.7) and 0.7 
(95% CI: 0.1-2.3), respectively. The risk point 
estimates were generally higher for other 
antihistamines than for loratadine.  
Since we only had one exposed case, our dataset 
did not allow separate analyses of hypospadias as a 
single outcome or as an outcome in combination with 
other congenital malformations. Such an analysis 
might have been useful in order to examine the 
presence of surveillance bias, as hypospadias occur in 
clusters with other malformations in some children. 
4.  Discussion 
The current study has shown that maternal 
exposure to loratadine does not appear to be 
associated with an increased risk of hypospadias 
compared with other antihistamines. In fact, the risk 
point estimates for hypospadias were higher with 
maternal exposure to other antihistamines compared 
with loratadine. Thus, our risk estimates do not 
corroborate the findings in the Swedish study [19] 
that initiated the hypospadias debate. However our 
risk estimates had limited statistical precision and an 
effect similar to that in the Swedish study cannot be 
ruled out entirely. 
Table 2. The association between hypospadias recorded within 
six months postpartum and maternal use of antihistamines 
according to time of exposure, odds ratios (OR) and 95% 
confidence intervals (CI) 
Time of exposure  Crude 
OR  
(95% CI) 
*Adjusted 
OR  
(95% CI) 
 1989-2002 
**Adjusted 
OR  
(95% CI) 
1991-2002 
Exposure 30 days before conception 
and first trimester :  
    
   Loratadine   1.3 (0.0-
9.3) 
1.4 (0.0-10.6)  1.4 (0.0-
10.5) 
   Other antihistamines  1.7 (0.4-
5.2) 
1.8 (0.4-5.3)  1.9 (0.5-5.8) 
Exposure first and second trimester :       
   Loratadine   0.7 (0.0-
4.4) 
0.7 (0.0-4.8)  0.8 (0.0-4.9) 
   Other antihistamines  1.4 (0.3-
4.9) 
1.4 (0.3-4.9)  1.6 (0.3-5.5) 
Exposure during pregnancy :       
   Loratadine   0.5 (0.0-
3.0) 
0.5 (0.0-3.2)  0.5 (0.0-3.3) 
   Other antihistamines  1.0 (0.2-
3.3) 
1.0 (0.2-3.3)  1.0 (0.2-3.4) 
*Adjusted for maternal age, birth order, ovulation-inducing drugs, maternal 
epilepsy, maternal diabetes and preeclampsia. 
**Adjusted for smoking, maternal age, birth order, ovulation-inducing drugs, 
maternal epilepsy, maternal diabetes and preeclampsia. 
 
Our case-control study had complete and 
independent registration of birth, birth outcome, and 
prescription data which prevented selection bias and 
some types of information bias; since the study was 
based on routinely recorded data, independent of the 
diagnosis. Importantly, there was no risk of recall 
bias, which can invalidate case-control studies that 
solely rely on interviews [27]. Although smaller than 
the Swedish Birth Registry, the database we used is 
one of the largest in the world for studying the safety 
of drugs used in pregnancy and previous studies 
have shown high data quality in both the prescription 
database and the Birth Registry [25,28]. Coding errors 
occur in less than 0.5 percent of cases in the 
prescription database [28].  
Our study was based on the HDR, and it is 
known that discharge diagnoses listed in discharge 
registries are not always accurate. We reviewed 43 
records of the hypospadias cases in our study and Int. J. Med. Sci. 2006, 3 
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found only three to be misclassified. Generally, lack 
of specificity, biases risk estimates towards unity. 
However, our prevalence of hypospadias corresponds 
to the prevalence reported in other datasets.  
Loratadine is also sold "over the counter" in 
Denmark and since the prescription databases do not 
capture information regarding "over the counter" 
medication, the exposure information may be 
incomplete. Incomplete exposure information in the 
current study may bias the results towards unity as 
well.  
Because of our reliance on dispensing 
information in the record linkage study, we do not 
know whether the women in the study actually took 
the drugs. However, the fact that patients are 
required to pay partially for the costs themselves is 
likely to have improved compliance.  
We were able to adjust for possible confounding 
factors except for the years 1989 and 1990, where we 
did not have information regarding smoking. 
However, in our study, adjustment for the available 
confounding variables did not change the unadjusted 
risk estimates substantially, implying that these 
variables were no major confounders. Since the 
development of the external organs is initiated in the 
early fetal period, some of the studied variables such 
as preeclampsia should be interpreted as biological 
characterization  of infants born with hypospadias 
rather than possible causal factors. 
Our data are in line with the few other existing 
studies. Thus, in a recently conducted study by the 
CDC no association between maternal use of 
loratadine and second- or third-degree hypospadias 
was demonstrated [22]. Similarly, in an Israeli study 
[20], no increased risk of hypospadias was 
demonstrated in the loratadine group compared with 
other antihistamines. Moretti and coworkers found in 
a multi center study [21] that maternal exposure to 
loratadine was not associated with major 
malformations. 
However, the infrequent maternal use of 
loratadine and the prevalence of hypospadias have a 
major impact on sample size requirements for 
providing the definitive assurances of the safety of 
loratadine to the unborn child [29]. Thus, to rule out a 
doubling of the risk of hypospadias would, based on 
our registries, require a study with 1,350 cases of 
hypospadias and 13,500 controls (power 80 percent 
and 0.5% exposure prevalence among controls).  
5.  Conclusion 
In conclusion, maternal exposure to loratadine 
does not appear to be associated with an increased 
risk of hypospadias compared to other 
antihistamines. However, the statistical precision of 
our risk estimates was limited. 
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